VACCINOLOGY • IMMUNOLOGY • BIOTECHNOLOGY

VLP Vaccines: Structure, Immunological Mechanisms and Applications

Exploring virus-like particles as innovative vaccine platforms for infectious disease prevention, antigen presentation and next-generation immunotherapy.

1. Introduction to Virus-Like Particle (VLP) Vaccines

Virus-like particles (VLPs) are nanoscale structures composed of viral structural proteins that spontaneously assemble into particles resembling authentic viruses. Although they reproduce important morphological and antigenic characteristics of viruses, conventional VLP vaccine particles lack the complete viral genome required for viral replication.

This distinctive combination of structural similarity and lack of a replication-competent viral genome makes VLPs an attractive platform for vaccine development. Their repetitive surface organization allows the immune system to recognize viral antigens efficiently and initiate specific immune responses.

VLP technology has contributed to the development of vaccines against several important infectious diseases, including human papillomavirus (HPV), hepatitis B virus (HBV) and hepatitis E virus (HEV). The platform is also being investigated for malaria and other emerging infectious diseases.

2. Structure and Characteristics of VLPs

VLPs are assembled from one or more viral structural proteins, including capsid proteins or envelope proteins. These proteins interact through molecular recognition and self-assembly processes to form organized nanoparticles.

Main Structural Characteristics

• Capsid proteins: Structural proteins that form the outer shell of many non-enveloped VLPs.
• Envelope proteins: Viral membrane-associated proteins that can contribute to the formation of enveloped VLPs.
• Surface antigens: Exposed proteins or epitopes recognized by antibodies and immune cells.
• Particle architecture: An organized and repetitive structure that resembles the native viral particle.
• Genetic material: Conventional recombinant VLP vaccines lack the complete viral genome necessary for productive viral replication.

Depending on their composition, VLPs can be classified into different structural categories.

3. How Do VLP Vaccines Activate the Immune System?

One of the most important advantages of VLPs is their capacity to stimulate both innate and adaptive immune responses. Their repetitive surface architecture allows multiple copies of an antigen to interact with immune receptors simultaneously.

3.1 Antigen Recognition and B-Cell Activation

VLP surface antigens can bind to specific B-cell receptors. The repetitive organization of these antigens promotes receptor clustering and can facilitate B-cell activation.

Activated B cells can differentiate into antibody-producing plasma cells and memory B cells, supporting both immediate and long-term humoral immunity.

3.2 Antigen Uptake by Antigen-Presenting Cells

Antigen-presenting cells (APCs), including dendritic cells and macrophages, can internalize VLPs and process their associated antigens.

Processed antigenic peptides can subsequently be presented through major histocompatibility complex (MHC) molecules to T lymphocytes.

3.3 T-Cell Responses

Depending on their design and delivery system, VLP vaccines can promote CD4+ T-cell responses and, in some circumstances, CD8+ T-cell responses.

CD4+ T helper cells support B-cell differentiation, antibody production and immune memory. CD8+ cytotoxic T cells can recognize and destroy infected cells when appropriate antigen presentation pathways are activated.

3.4 Immunological Memory

Following vaccination, memory B cells and T cells may persist and respond more rapidly when the immune system encounters the corresponding antigen again.

4. Production Technologies for VLP Vaccines

VLP manufacturing involves recombinant expression of selected viral structural proteins, followed by particle assembly, purification and quality assessment.

Several expression systems are used depending on the complexity of the antigen, particle architecture, production requirements and desired product characteristics.

4.1 Yeast Expression Systems

Yeast systems are widely used for recombinant viral antigen production. They have contributed significantly to the development of hepatitis B and HPV vaccine technologies.

4.2 Insect Cell Expression Systems

Baculovirus-based insect cell expression systems allow the production of complex viral proteins and VLP structures. They are particularly useful for certain recombinant antigen and particle designs.

4.3 Mammalian Cell Expression Systems

Mammalian cells can support complex protein folding, assembly and post-translational modifications. These characteristics can be important for VLPs containing membrane-associated or structurally complex proteins.

4.4 Bacterial Expression Systems

Bacterial systems can offer rapid growth and cost-effective recombinant protein production. They are useful for selected VLP designs, although some complex proteins may require alternative expression platforms.

4.5 Plant-Based Expression Systems

Plant molecular farming is an emerging approach for producing recombinant vaccine antigens and VLPs. It has attracted interest because of its potential scalability and alternative manufacturing infrastructure.

5. Major Applications of VLP Vaccines

5.1 Human Papillomavirus (HPV) Vaccines

HPV vaccines represent one of the most successful applications of VLP technology.

These vaccines use recombinant L1 major capsid proteins that self-assemble into particles resembling the HPV capsid. The resulting VLPs display conformational epitopes that stimulate the production of neutralizing antibodies.

HPV vaccination is an important preventive strategy against infections caused by targeted HPV types and the associated cervical and other HPV-related cancers.

5.2 Hepatitis B Virus (HBV) Vaccines

Recombinant hepatitis B vaccines use hepatitis B surface antigen (HBsAg), which can self-assemble into noninfectious subviral particles.

These particles stimulate protective antibody responses against HBsAg and are an established example of recombinant particle-based vaccine technology.

5.3 Hepatitis E Virus (HEV) Vaccines

VLP-related antigen technology has also been applied to hepatitis E vaccine development. Recombinant HEV capsid-derived antigens form particulate structures that can stimulate immune responses.

A recombinant hepatitis E vaccine has been licensed in China, demonstrating the potential of particle-based antigen platforms beyond HPV and HBV.

5.4 Malaria Vaccine Development

VLP technology has also contributed to malaria vaccine development.

The RTS,S malaria vaccine, also known as Mosquirix, uses a recombinant fusion of Plasmodium falciparum circumsporozoite protein with hepatitis B surface antigen. These proteins assemble into particles that display malaria antigens.

This approach illustrates how a viral protein scaffold can be used to present antigens from a different pathogen.

5.5 Emerging Applications in Cancer Immunotherapy

Researchers are investigating engineered VLPs as platforms for delivering tumor-associated antigens and stimulating targeted immune responses.

These approaches include experimental therapeutic vaccines designed to improve antigen presentation and activate tumor-specific immune responses. Most remain at preclinical or clinical research stages and should not be confused with established cancer treatments.

6. VLP Vaccines Compared with Conventional Vaccine Platforms

VLP vaccines have several distinct characteristics compared with traditional live-attenuated, inactivated and soluble protein vaccine platforms.

Actual immunogenicity, safety and effectiveness depend on the antigen, formulation, adjuvant, administration route and specific vaccine product.

7. Advantages of VLP-Based Vaccines

• Non-replicating design: Conventional VLPs lack the complete viral genome required for productive viral replication.
• High antigen density: Repetitive antigen presentation can promote strong B-cell receptor activation.
• Structural similarity: VLPs can preserve important conformational epitopes found on native viruses.
• Versatile engineering: Selected antigens can be displayed on different particle scaffolds.
• Multiple expression platforms: Production can be adapted to yeast, insect, mammalian, bacterial or plant systems.
• Established clinical applications: Several licensed human vaccines demonstrate the clinical potential of VLP technology.

8. Challenges and Limitations in VLP Vaccine Development

Despite their promising characteristics, VLP vaccines present important technical, biological and regulatory challenges.

• Particle assembly: Achieving consistent particle formation can be technically demanding.
• Structural stability: Temperature, pH and formulation conditions can influence particle integrity.
• Manufacturing costs: Complex production and purification processes can affect scalability.
• Antigen selection: The choice and arrangement of epitopes influence immune recognition.
• Quality control: Particle size, morphology, antigenicity, purity and potency require rigorous assessment.
• Immune variability: Individual immune responses can differ according to age, health status and previous antigen exposure.
• Clinical translation: Promising laboratory findings do not automatically translate into effective human vaccines.

9. Future Perspectives in VLP Vaccine Research

Advances in structural biology, protein engineering, computational design and recombinant biotechnology are expanding the possibilities of VLP vaccine development.

Important research directions include:

• Multivalent VLP vaccines: Displaying multiple antigens on a single particle to target several pathogen variants.
• Chimeric VLPs: Incorporating foreign antigens into established particle scaffolds.
• Computational protein design: Designing new self-assembling structures with controlled antigen presentation.
• Improved adjuvant systems: Optimizing immune activation and response quality.
• Therapeutic VLP platforms: Investigating applications in cancer immunotherapy and other non-infectious diseases.
• Advanced manufacturing: Improving particle characterization, purification, stability and production scalability.

These developments could contribute to more adaptable vaccine platforms and new approaches to preventive and therapeutic immunization.

10. Scientific References and Further Reading

The following peer-reviewed publications provide scientific evidence and further reading on VLP structure, immunogenicity, vaccine production and clinical applications.